Entero Financial Statements From 2010 to 2025

ENTO Stock   0.44  0.02  4.35%   
Entero Therapeutics,'s financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Entero Therapeutics,'s valuation are provided below:
Market Capitalization
2.2 M
Earnings Share
(8.07)
We have found one hundred twenty available fundamental signals for Entero Therapeutics,, which can be analyzed and compared to other ratios and to its rivals. Self-guided Investors are advised to verify Entero Therapeutics,'s prevailing fundamentals against the trend between 2010 and 2025 to make sure the company can sustain itself down the road. As of the 1st of August 2025, Market Cap is likely to drop to about 2.7 M. In addition to that, Working Capital is likely to drop to -1,059
Check Entero Therapeutics, financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Entero Therapeutics,'s main balance sheet or income statement drivers, such as Depreciation And Amortization of 46.5 K, Selling General Administrative of 13.8 K or Other Operating Expenses of 14.8 K, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 0.0476. Entero financial statements analysis is a perfect complement when working with Entero Therapeutics, Valuation or Volatility modules.
  
Build AI portfolio with Entero Stock
Check out the analysis of Entero Therapeutics, Correlation against competitors.
To learn how to invest in Entero Stock, please use our How to Invest in Entero Therapeutics, guide.

Entero Therapeutics, Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets89.7 M85.4 M14.6 M
Slightly volatile
Short and Long Term Debt Total133.5 K140.5 K280 K
Slightly volatile
Other Current Liabilities25.7 M24.5 MM
Slightly volatile
Total Current Liabilities28.9 M27.5 M6.1 M
Slightly volatile
Property Plant And Equipment Net142.7 K126.8 K106.2 K
Slightly volatile
Accounts Payable1.5 MM1.1 M
Slightly volatile
Cash155.3 K163.5 K1.4 M
Slightly volatile
Non Current Assets Total2.2 M1.9 M1.7 M
Slightly volatile
Non Currrent Assets Other93.3 K98.3 K407.4 K
Very volatile
Cash And Short Term Investments155.3 K163.5 K1.4 M
Slightly volatile
Common Stock Shares Outstanding3.6 M3.4 M463.7 K
Slightly volatile
Liabilities And Stockholders Equity89.7 M85.4 M14.6 M
Slightly volatile
Non Current Liabilities Total56.1 K59 K799.1 K
Pretty Stable
Other Current Assets87.5 M83.3 M11.2 M
Slightly volatile
Other Stockholder Equity208.4 M198.5 M74.8 M
Slightly volatile
Total Liabilities29 M27.6 M6.8 M
Slightly volatile
Total Current Assets87.7 M83.5 M12.9 M
Slightly volatile
Net Receivables101.6 K107 K758.3 K
Pretty Stable
Good Will1.5 M1.9 MM
Slightly volatile
Short Term Investments72.7751.1778.8088
Slightly volatile
Short Term Debt77.4 K81.5 K742.6 K
Very volatile
Intangible Assets3.5 M3.3 M1.4 M
Slightly volatile
Common Stock356475328
Pretty Stable
Capital Lease Obligations176.1 K140.5 K127.6 K
Slightly volatile
Property Plant And Equipment Gross308 K214.6 K188.6 K
Slightly volatile
Short and Long Term Debt662.7 K704.7 K581.3 K
Slightly volatile
Capital Stock64.8 M61.7 M7.9 M
Slightly volatile
Non Current Liabilities Other5.6 M6.3 M6.9 M
Slightly volatile

Entero Therapeutics, Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization46.5 K48.9 K79.1 K
Slightly volatile
Selling General Administrative13.8 K14.6 KM
Slightly volatile
Other Operating Expenses14.8 K15.6 KM
Slightly volatile
Research Development859904M
Slightly volatile
Total Operating Expenses14.8 K15.6 KM
Slightly volatile
Cost Of Revenue25 K26.3 K560.4 K
Slightly volatile
Interest Income3.5 K2.9 K1.5 K
Slightly volatile
Interest Expense19.2 K20.2 KM
Slightly volatile
Reconciled Depreciation46.5 K48.9 K432.2 K
Slightly volatile
Selling And Marketing Expenses124.8 K140.4 K153.1 K
Slightly volatile

Entero Therapeutics, Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Depreciation46.5 K48.9 K221.9 K
Pretty Stable
End Period Cash Flow175.7 K185 K1.5 M
Slightly volatile
Begin Period Cash Flow2.2 M3.7 M1.5 M
Slightly volatile
Stock Based Compensation533.9 K631.6 K306.6 K
Slightly volatile
Issuance Of Capital Stock5.9 M6.2 M15.4 M
Very volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Average Payables887.6 K1.8 M1.1 M
Slightly volatile
Capex To Depreciation16.1415.377.8331
Slightly volatile
Payables Turnover0.05770.06070.435
Slightly volatile
Cash Per Share0.03340.03511.9 K
Very volatile
Days Payables Outstanding6.5 K6.2 KK
Slightly volatile
Intangibles To Total Assets0.01870.01970.4195
Slightly volatile
Current Ratio3.183.03051.2791
Slightly volatile
Capex Per Share1.271.34372
Pretty Stable
Average Receivables301.3 K317.1 K1.9 M
Slightly volatile
Interest Debt Per Share0.02870.0302841
Pretty Stable
Debt To Assets0.00160.00160.1671
Slightly volatile
Days Of Payables Outstanding6.5 K6.2 KK
Slightly volatile
Ebt Per Ebit1.290.99991.155
Very volatile
Long Term Debt To Capitalization0.630.710.7732
Slightly volatile
Quick Ratio2.883.030539.6675
Very volatile
Net Income Per E B T783KK
Slightly volatile
Cash Ratio0.00560.00590.2859
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.010.941.1908
Very volatile
Debt Ratio0.00160.00160.1671
Slightly volatile

Entero Therapeutics, Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap2.7 M2.9 M28.5 M
Slightly volatile

Entero Fundamental Market Drivers

Cash And Short Term Investments163.5 K

About Entero Therapeutics, Financial Statements

Entero Therapeutics, investors utilize fundamental indicators, such as revenue or net income, to predict how Entero Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue2.2 MM
Cost Of Revenue26.3 K25 K

Pair Trading with Entero Therapeutics,

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Entero Therapeutics, position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Entero Therapeutics, will appreciate offsetting losses from the drop in the long position's value.

Moving together with Entero Stock

  0.65A Agilent Technologies Earnings Call This WeekPairCorr

Moving against Entero Stock

  0.58TOVX Theriva BiologicsPairCorr
  0.49ERNA Eterna TherapeuticsPairCorr
  0.48MOLN Molecular PartnersPairCorr
  0.41CLOV Clover Health Investments Earnings Call This WeekPairCorr
  0.37TELO Telomir Pharmaceuticals,PairCorr
The ability to find closely correlated positions to Entero Therapeutics, could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Entero Therapeutics, when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Entero Therapeutics, - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Entero Therapeutics, to buy it.
The correlation of Entero Therapeutics, is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Entero Therapeutics, moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Entero Therapeutics, moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Entero Therapeutics, can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Entero Therapeutics, offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Entero Therapeutics,'s financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Entero Therapeutics, Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Entero Therapeutics, Stock:
Check out the analysis of Entero Therapeutics, Correlation against competitors.
To learn how to invest in Entero Stock, please use our How to Invest in Entero Therapeutics, guide.
You can also try the Headlines Timeline module to stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Entero Therapeutics,. If investors know Entero will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Entero Therapeutics, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(8.07)
Return On Assets
(0.05)
Return On Equity
(0.33)
The market value of Entero Therapeutics, is measured differently than its book value, which is the value of Entero that is recorded on the company's balance sheet. Investors also form their own opinion of Entero Therapeutics,'s value that differs from its market value or its book value, called intrinsic value, which is Entero Therapeutics,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Entero Therapeutics,'s market value can be influenced by many factors that don't directly affect Entero Therapeutics,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Entero Therapeutics,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if Entero Therapeutics, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Entero Therapeutics,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.